The new capital injection follows OrbiMed’s initial US$35 million investment in February, which was aimed at accelerating the rollout of Curodont in the US. That capital supported the scaling of clinical and sales teams, the development of distribution infrastructure and deeper engagement with dental professionals across key markets.

Curodont is a non-invasive treatment designed to arrest and remineralise initial carious lesions. Its biomimetic formulation interacts with calcium and phosphate ions in saliva to promote enamel regeneration at the site of demineralisation. As a needle- and drill-free alternative to conventional restorative approaches, it supports minimally invasive dentistry by preserving natural tooth structure and reducing operative time.

Drs Haleh and Golnar Abivardi, founders and co-CEOs of vVARDIS, said: “We are thrilled to expand our partnership with OrbiMed as we enter this next phase of growth. This additional funding, combined with OrbiMed’s strategic expertise, will accelerate our ability to serve dental professionals and patients globally. As dentists, we are delighted to bring forward a drill-free treatment for early decay that promises to elevate the standard of care for patients around the world.”

Matthew Rizzo, general partner at OrbiMed, commented: “After our initial investment, we’ve seen first-hand the momentum vVARDIS is building in the dental market with its Curodont products. We came in at a pivotal moment—just as the product began gaining real traction—and the company’s rapid progress and the market’s response have since reinforced our belief in the significant opportunities ahead. That’s why we’re excited to deepen our commitment and expand our investment to support vVARDIS in its next phase of growth.”

According to vVARDIS, it is the fastest-growing dental manufacturer in its category. In a recent press release, the company also stated that, since January 2024, more than one million teeth have been treated with Curodont in the US and that nearly 10% of dental practices in the country are now offering the treatment, which has been used in more than 400,000 patients.

Tags: